Phase II Trial of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Adenocarcinoma of the Prostate.

Trial Profile

Phase II Trial of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Adenocarcinoma of the Prostate.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2016

At a glance

  • Drugs Paclitaxel (Primary) ; Bicalutamide; Leuprorelin
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Jan 2009 Planned patient numbers amended from 40 to 14 as reported by ClinicalTrials.gov.
    • 30 Jan 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top